Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Laufer

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Journal of Medicinal Chemistry|December 22, 2023
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor InhibitorsKristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, et al.
Journal of Chemical Information and Modeling|June 17, 2023
Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2Débora Bublitz Anton, Júlia Galvez Bulhões Pedreira, Maria Luiza Zvirtes, et al.
Nature Chemical Biology|December 27, 2011
Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitorSolveigh C Koeberle, Johannes Romir, Stefan Fischer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2024
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i>-mutant cancersRobin A Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Journal of Medicinal Chemistry|June 1, 2018
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine ScaffoldMichael Forster, Apirat Chaikuad, Teodor Dimitrov, et al.
Journal of Medicinal Chemistry|December 6, 2014
Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
Journal of Medicinal Chemistry|April 11, 2024
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S<sub>N</sub>Ar ElectrophilesMoritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Cell Chemical Biology|November 15, 2016
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding PocketMichael Forster, Apirat Chaikuad, Silke M Bauer, et al.
Journal of Medicinal Chemistry|December 16, 2016
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3Felix Muth, Ahmed El-Gokha, Francesco Ansideri, et al.
Journal of Medicinal Chemistry|February 27, 2015
Correction to Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Journal of Medicinal Chemistry|December 22, 2023
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor InhibitorsKristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, et al.
Journal of Chemical Information and Modeling|June 17, 2023
Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2Débora Bublitz Anton, Júlia Galvez Bulhões Pedreira, Maria Luiza Zvirtes, et al.
Nature Chemical Biology|December 27, 2011
Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitorSolveigh C Koeberle, Johannes Romir, Stefan Fischer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2024
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i>-mutant cancersRobin A Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Journal of Medicinal Chemistry|June 1, 2018
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine ScaffoldMichael Forster, Apirat Chaikuad, Teodor Dimitrov, et al.
Journal of Medicinal Chemistry|December 6, 2014
Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
Journal of Medicinal Chemistry|April 11, 2024
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S<sub>N</sub>Ar ElectrophilesMoritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Cell Chemical Biology|November 15, 2016
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding PocketMichael Forster, Apirat Chaikuad, Silke M Bauer, et al.
Journal of Medicinal Chemistry|December 16, 2016
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3Felix Muth, Ahmed El-Gokha, Francesco Ansideri, et al.
Journal of Medicinal Chemistry|February 27, 2015
Correction to Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
Pageof 19